A GPR55 Receptor Agonist Reduced Morphine Reward and Physical Dependence in Mice
The atypical cannabinoid O-1602, which activates the GPR55 receptor, reduced both the rewarding effects and physical dependence symptoms of morphine in mice.
Quick Facts
What This Study Found
Researchers tested whether O-1602, a compound that activates the GPR55 receptor (sometimes called a third cannabinoid receptor), could affect morphine reward and dependence in mice.
In a conditioned place preference test, O-1602 at lower doses (0.2 and 1 mg/kg) reduced the acquisition of morphine reward, meaning mice spent less time in the chamber associated with morphine. At all three doses tested, O-1602 also reduced the expression of established morphine preference.
For physical dependence, O-1602 at the highest dose (5 mg/kg) significantly reduced withdrawal symptoms including jumping and diarrhea when naloxone-precipitated withdrawal was triggered after repeated morphine administration. The highest dose also increased locomotor activity on its own.
Key Numbers
O-1602 at 0.2 and 1 mg/kg reduced acquisition of morphine CPP. All three doses (0.2, 1, 5 mg/kg) reduced expression of morphine CPP. O-1602 at 5 mg/kg reduced jumping and diarrhea during naloxone-precipitated morphine withdrawal. The 5 mg/kg dose increased locomotor activity.
How They Did This
Male mice were tested in a biased conditioned place preference model using morphine (40 mg/kg). O-1602 was tested at 0.2, 1, and 5 mg/kg for effects on acquisition and expression of morphine preference. For physical dependence, mice received escalating morphine doses over three days, and withdrawal was triggered with naloxone. Locomotor activity was recorded throughout.
Why This Research Matters
Opioid dependence remains a major health challenge. Finding that a GPR55 agonist can reduce both the rewarding effects and physical dependence aspects of morphine opens a potential new avenue for addressing opioid use disorder through a cannabinoid-related receptor that is distinct from CB1 and CB2.
The Bigger Picture
GPR55 is an emerging receptor in cannabinoid pharmacology. This study adds to evidence that the broader endocannabinoid system, beyond just CB1 and CB2 receptors, interacts with opioid pathways. Understanding these interactions could eventually lead to new approaches for treating opioid dependence.
What This Study Doesn't Tell Us
This was a mouse study with a relatively simple behavioral paradigm. The highest effective dose (5 mg/kg) also increased locomotor activity, which could confound interpretation. GPR55 pharmacology is not fully characterized, and O-1602 may have off-target effects. Translation to human opioid dependence treatment would require extensive further research.
Questions This Raises
- ?Could GPR55-targeting drugs be developed as treatments for opioid use disorder in humans?
- ?Does GPR55 interact with other aspects of the endocannabinoid system that are relevant to addiction?
Trust & Context
- Key Stat:
- GPR55 agonist reduced both morphine reward and physical withdrawal symptoms
- Evidence Grade:
- This is an animal study testing a relatively novel pharmacological target. While the results are promising, GPR55 research is still in early stages and clinical translation is distant.
- Study Age:
- Published in 2016. GPR55 research has continued but remains largely preclinical.
- Original Title:
- The effect of O-1602, an atypical cannabinoid, on morphine-induced conditioned place preference and physical dependence.
- Published In:
- Pharmacological reports : PR, 68(3), 592-7 (2016)
- Database ID:
- RTHC-01087
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What is GPR55?
GPR55 is a receptor sometimes called the "third cannabinoid receptor" because it responds to some cannabinoid compounds, though it is structurally different from CB1 and CB2 receptors. It is involved in pain modulation and other functions, but its full role is still being characterized.
Could this lead to new treatments for opioid addiction?
The findings suggest GPR55 as a potential pharmacological target, but substantial research would be needed before any clinical application. The current evidence is limited to one mouse study with one compound, and GPR55-targeting drugs for human use have not been developed.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-01087APA
Alavi, Mohaddeseh Sadat; Hosseinzadeh, Hossein; Shamsizadeh, Ali; Roohbakhsh, Ali. (2016). The effect of O-1602, an atypical cannabinoid, on morphine-induced conditioned place preference and physical dependence.. Pharmacological reports : PR, 68(3), 592-7. https://doi.org/10.1016/j.pharep.2015.12.009
MLA
Alavi, Mohaddeseh Sadat, et al. "The effect of O-1602, an atypical cannabinoid, on morphine-induced conditioned place preference and physical dependence.." Pharmacological reports : PR, 2016. https://doi.org/10.1016/j.pharep.2015.12.009
RethinkTHC
RethinkTHC Research Database. "The effect of O-1602, an atypical cannabinoid, on morphine-i..." RTHC-01087. Retrieved from https://rethinkthc.com/research/alavi-2016-the-effect-of-o1602
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.